









Markets
/
Stocks
/
nasdaq-txmd
/

TherapeuticsMD Inc

TXMD

1.090USD

+0.010+0.93%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

12.62MMarket Cap

LossP/E TTM



TherapeuticsMD Inc

1.090

+0.010+0.93%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

117 / 175

Overall Ranking

421 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.76M.

Undervalued

The company’s latest PE is -27.40, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 5.28M shares, increasing 21.65% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 379.00K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.46, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 952.00K, representing a year-over-year increase of 306.84%, while its net profit experienced a year-over-year increase of 150.55%.

Score

Industry at a Glance

Previous score

8.46

Change



Financials

7.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.38

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.50

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -27.15, which is -100.80% below the recent high of 0.22 and 80.80% above the recent low of -5.21.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 117/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.94, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 1.20 and the support level at 1.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.94

Change

0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.001

Neutral

RSI(14)

47.657

Neutral

STOCH(KDJ)(9,3,3)

13.091

Oversold

ATR(14)

0.047

Low Volatility

CCI(14)

-27.788

Neutral

Williams %R

78.947

Sell

TRIX(12,20)

-0.151

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.078

Buy

MA10

1.087

Buy

MA20

1.094

Sell

MA50

1.119

Sell

MA100

1.202

Sell

MA200

1.119

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 45.63%, representing a quarter-over-quarter increase of 47.45%. The largest institutional shareholder is The Vanguard, holding a total of 379.00K shares, representing 3.27% of shares outstanding, with 2.57% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Rubric Capital Management LP

2.95M

+147.18%

Clearline Capital LP

635.22K

The Vanguard Group, Inc.

Star Investors

381.94K

-1.46%

Tejara Capital Ltd.

344.60K

-12.69%

Adar1 Capital Management LLC

270.16K

Morgan Stanley & Co. LLC

130.12K

-0.24%

BlackRock Institutional Trust Company, N.A.

116.13K

Geode Capital Management, L.L.C.

111.51K

+2.93%

Walker (Marlan D)

73.64K

+3.94%

Collins (Cooper C)

60.52K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.20, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.57. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.